Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors

This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report results from Cohort D of the CHRYSALIS-2 study on efforts to identify predictive biomarkers for treatment with RYBREVANT® (amivantamab-vmjw) plus lazertinib among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in the post-osimertinib setting, (Abstract #9013).Longer-term follow-up data from the CHRYSALIS study evaluating RYBREVANT® in combination with lazertinib as a first-line therapy in patients with locally advanced or metastatic NSCLC with common EGFR mutations will be presented as a poster, (Abstract #9134).Updated safety results from the Phase 1b PALOMA study evaluating the investigational use of subcutaneous RYBREVANT® in patients with advanced solid tumors will also be presented as a poster, (Abstract #9126).GU Cancers A late-breaking oral presentation will report the final analysis from Cohor...

Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news